Appeal No. 2001-1586 Page 10
Application No. 08/402,394
The second subgenus consists of the following compounds:
1. B(1-29) (Ala-Arg) A(1-21)
2. B(1-29) (Ser-Arg) A(1-21)
3. B(1-29) (Thr-Arg) A(1-21)
4. B(1-29) (Ala-Ala-Arg) A(1-21)
5. B(1-29) (Ala-Ser-Arg) A(1-21)
6. B(1-29) (Ala-Thr-Arg) A(1-21)
7. B(1-29) (Ser-Ala-Arg) A(1-21)
8. B(1-29) (Ser-Ser-Arg) A(1-21)
9. B(1-29) (Ser-Thr-Arg) A(1-21)
10. B(1-29) (Thr-Ala-Arg) A(1-21)
11. B(1-29) (Thr-Ser-Arg) A(1-21)
12. B(1-29) (Thr-Thr-Arg) A(1-21)
Amino acid residue 30 of the B chain of human insulin is Thr. See, e.g., Figure 1 of
Thim. Thus, compound 3 enumerated in the above table is the compound required by
claim 33 on appeal, i.e., B(1-30)-Arg-A(1-21).
Upon return of the application, the examiner and appellants should carefully
review the disclosure of the insulin precursors described in Markussen ‘212 in light of
the guidance provided by In re Petering. If in fact one of the preferred subgenera of
Markussen ‘212 consists of the 12 compounds set forth in the above table which
includes the compound of claim 33, it may be reasonable for the examiner to conclude
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007